Investigation of Immune Amnesia Following Measles Infection in Select African Regions

Status: Active_not_recruiting
Location: See all (2) locations...
Intervention Type: Biological
Study Type: Observational
SUMMARY

The goal of this observational study is to investigate the effects of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to subsequent illness in children aged 1-15 either with or without acute MeV infection.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 15
Healthy Volunteers: t
View:

• Aged 1 to 15 years.

• Ability of the participant's legal or culturally acceptable representative to provide informed consent.

• Ability to give assent, as appropriate.

• Stated willingness of parent/guardian and participant as appropriate, to comply with all study procedures.

• Willingness to receive rabies vaccine.

• Meet the criteria for assignment to Group 1 or Group 2, as follows:

• Group 1, cases (acute MeV infection):

• Clinical signs and symptoms suggestive of acute MeV infection (Koplik spots or skin rash) AND

• Laboratory confirmed measles:

• Upper respiratory specimen (swab) PCR for measles positive, OR

• Serum IgM for measles positive.

• Group 2, controls (no acute MeV infection):

• No clinical signs and symptoms suggestive of acute MeV infection (Koplik spots or skin rash) AND

• Upper respiratory specimen (swab) PCR negative for MeV AND

• Serum measles IgM negative AND

• Serum measles IgG positive and previously vaccinated for measles (2nd dose will be offered if appropriate). If serum measles IgG is negative, participant must be willing to be vaccinated regardless of prior measles vaccine history to meet this criterion.

Locations
Other Locations
Guinea
Partnership of Clinical Research in Guinea, Partenariat Pour La Recherche Clinique en Guinée (PREGUI)
Conakry
Mali
University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako
Bamako
Time Frame
Start Date: 2024-01-16
Completion Date: 2026-06
Participants
Target number of participants: 256
Treatments
Group 1 - Actue MeV Infection
Participants have acute MeV infection.
Group 2 - No Actue MeV Infection
Participants do not have acute MeV infection.
Related Therapeutic Areas
Sponsors
Leads: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Johns Hopkins University

This content was sourced from clinicaltrials.gov